Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer
- 1 January 2009
- journal article
- clinical trial
- Published by Elsevier BV in Annals Of Oncology
- Vol. 20 (1), 182-187
- https://doi.org/10.1093/annonc/mdn543
Abstract
Glioblastoma multiforme (GBM), the most frequent malignant brain tumor, has a poor prognosis, but is relatively sensitive to radiation. Both gemcitabine and its metabolite difluorodeoxyuridine (dFdU) are potent radiosensitizers. The aim of this phase 0 study was to investigate whether gemcitabine passes the blood-tumor barrier, and is phosphorylated in the tumor by deoxycytidine kinase (dCK) to gemcitabine nucleotides in order to enable radiosensitization, and whether it is deaminated by deoxycytidine deaminase (dCDA) to dFdU. Gemcitabine was administered at 500 or 1000 mg/m(2) just before surgery to 10 GBM patients, who were biopsied after 1-4 h. Plasma gemcitabine and dFdU levels varied between 0.9 and 9.2 microM and 24.9 and 72.6 microM, respectively. Tumor gemcitabine and dFdU levels varied from 60 to 3580 pmol/g tissue and from 29 to 72 nmol/g tissue, respectively. The gene expression of dCK (beta-actin ratio) varied between 0.44 and 2.56. The dCK and dCDA activities varied from 1.06 to 2.32 nmol/h/mg protein and from 1.51 to 5.50 nmol/h/mg protein, respectively. These enzyme levels were sufficient to enable gemcitabine phosphorylation, leading to 130-3083 pmol gemcitabine nucleotides/g tissue. These data demonstrate for the first time that gemcitabine passes the blood-tumor barrier in GBM patients. In tumor samples, both gemcitabine and dFdU concentrations are high enough to enable radiosensitization, which warrants clinical studies using gemcitabine in combination with radiation.Keywords
Funding Information
- Eli Lilly & Company
This publication has 36 references indexed in Scilit:
- Differential Radiosensitizing Potential of Temozolomide in MGMT Promoter Methylated Glioblastoma Multiforme Cell LinesInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Nucleoside RadiosensitizersPublished by Springer Science and Business Media LLC ,2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Role of gemcitabine in cancer therapyFuture Oncology, 2005
- Combined Modality Therapy of Gemcitabine and RadiationThe Oncologist, 2005
- Genetic Pathways to GlioblastomaCancer Research, 2004
- Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resistance Updates, 2002
- Radiotherapy of glioblastoma multiformeStrahlentherapie Und Onkologie, 1998
- Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boostInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytomaInternational Journal of Radiation Oncology*Biology*Physics, 1989